Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AML with a susceptible IDH1 mutation. Population pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xuemin, Wada, Russ, Poland, Bill, Kleijn, Huub Jan, Fan, Bin, Liu, Guowen, Liu, Hua, Kapsalis, Stephanie, Yang, Hua, Le, Kha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212730/
https://www.ncbi.nlm.nih.gov/pubmed/33493392
http://dx.doi.org/10.1111/cts.12959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212730/
https://www.ncbi.nlm.nih.gov/pubmed/33493392
http://dx.doi.org/10.1111/cts.12959

Ejemplares similares